TriangleHEALTH PROFESSIONAL · SOURCE READING
Targeted Therapy With Tyrosine Kinase Inhibitors (TKIs)
Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 13, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment Option Overview for CML
The optimal front-line treatment for patients with chronic-phase CML involves specific inhibitors of the BCR::ABL1 tyrosine kinase. Although imatinib mesylate has been extensively studied in patients with CML, TKIs with greater potency and selectivity for BCR::ABL1 than imatinib have also been evaluated.[1-4] Bariatric surgery may impede proper absorption of oral TKIs, resulting in suboptimal responses.[5]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice